Editas Medicine, Inc. (NASDAQ:EDIT – Free Report) – Stock analysts at HC Wainwright lifted their FY2026 earnings estimates for shares of Editas Medicine in a research report issued to clients and investors on Tuesday, November 10th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings per share of ($0.61) for the year, up from their prior estimate of ($0.66). The consensus estimate for Editas Medicine’s current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for Editas Medicine’s Q1 2027 earnings at ($0.21) EPS and Q2 2027 earnings at ($0.22) EPS.
Editas Medicine (NASDAQ:EDIT – Get Free Report) last announced its earnings results on Monday, November 9th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.04. Editas Medicine had a negative return on equity of 130.43% and a negative net margin of 144.95%. The company had revenue of $10.37 million during the quarter, compared to the consensus estimate of $4.46 million.
Several other equities research analysts also recently issued reports on the company. Guggenheim upgraded Editas Medicine from a “neutral” rating to a “buy” rating and set a $5.00 price objective on the stock in a report on Wednesday, September 23rd. Wall Street Zen upgraded Editas Medicine from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Wells Fargo & Company raised shares of Editas Medicine from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $4.00 to $6.00 in a research report on Thursday, October 8th. Ladenburg Thalmann & Co. Inc. initiated coverage on shares of Editas Medicine in a research note on Tuesday, August 18th. They issued a “buy” rating and a $6.00 price target for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Editas Medicine in a report on Wednesday, November 4th. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $5.83.
Check Out Our Latest Analysis on Editas Medicine
Editas Medicine Price Performance
Shares of EDIT opened at $2.38 on Thursday. Editas Medicine has a one year low of $1.66 and a one year high of $3.94. The stock has a 50-day moving average price of $2.67 and a 200 day moving average price of $2.69.
Hedge Funds Weigh In On Editas Medicine
Institutional investors have recently made changes to their positions in the stock. BlackRock Inc. bought a new stake in shares of Editas Medicine in the 2nd quarter worth approximately $34,312,000. ADAR1 Capital Management LLC bought a new position in Editas Medicine during the 2nd quarter worth $28,800,000. State Street Corp grew its stake in Editas Medicine by 60.6% during the 3rd quarter. State Street Corp now owns 7,038,580 shares of the company’s stock worth $18,089,000 after buying an additional 2,654,974 shares during the last quarter. Opaleye Management Inc. grew its stake in Editas Medicine by 100.4% during the 2nd quarter. Opaleye Management Inc. now owns 3,861,930 shares of the company’s stock worth $12,513,000 after buying an additional 1,934,933 shares during the last quarter. Finally, Renaissance Technologies LLC increased its position in Editas Medicine by 30.7% in the first quarter. Renaissance Technologies LLC now owns 3,972,160 shares of the company’s stock worth $9,811,000 after buying an additional 932,382 shares during the period. 71.90% of the stock is owned by institutional investors.
Editas Medicine Company Profile
Editas Medicine, Inc. is a biotechnology company developing genome-editing medicines for people with serious diseases. Its research uses CRISPR-based technologies, including CRISPR-Cas9 and Cas12a, to make targeted changes to DNA. Founded in 2013 and based in Cambridge, Massachusetts, the company conducts research and clinical development of potential treatments for genetic disorders. Its work has included approaches designed to edit genes in a patient’s cells, either outside the body or directly within the body.
Featured Articles
- Five stocks we like better than Editas Medicine
- Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-Off
- Palantir’s Real Washington Risk Isn’t the Budget—It’s Oversight
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.
